304 related articles for article (PubMed ID: 16550587)
1. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
[TBL] [Abstract][Full Text] [Related]
2. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
4. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
5. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
6. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors.
Ozao-Choy J; Buch K; Strauchen JA; Warner RR; Divino CM
J Surg Res; 2010 Jul; 162(1):22-5. PubMed ID: 20421108
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
8. [Fundic endocrine tumors and atrophic gastritis: the value of antrectomy].
Guillem P; Vlaeminck-Guillem V; Leteurtre E; Kornhauser R; Cortot A; Wemeau JL; Triboulet JP
Gastroenterol Clin Biol; 2002; 26(8-9):782-5. PubMed ID: 12434081
[TBL] [Abstract][Full Text] [Related]
9. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
Manfredi S; Pagenault M; de Lajarte-Thirouard AS; Bretagne JF
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
[TBL] [Abstract][Full Text] [Related]
10. Gastric carcinoids in patients with hypergastrinemia.
Jordan PH; Barroso A; Sweeney J
J Am Coll Surg; 2004 Oct; 199(4):552-5. PubMed ID: 15454137
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of patients with ECL cell-derived tumours.
Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
14. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
15. [Gastric carcinoid tumours. Is there a place for antrectomy?].
Guillem P
Ann Chir; 2005 Jun; 130(5):323-6. PubMed ID: 15890310
[TBL] [Abstract][Full Text] [Related]
16. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor.
Higham AD; Dimaline R; Varro A; Attwood S; Armstrong G; Dockray GJ; Thompson DG
Gastroenterology; 1998 Apr; 114(4):817-22. PubMed ID: 9516403
[TBL] [Abstract][Full Text] [Related]
17. Correlation between a short-term intravenous octreotide suppression test and response to antrectomy in patients with type-1 gastric neuroendocrine tumours.
Murugesan SV; Steele IA; Dimaline R; Poston GJ; Shrotri M; Campbell F; Varro A; Pritchard DM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):474-81. PubMed ID: 23249603
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia.
Hoshino M; Omura N; Yano F; Tsuboi K; Matsumoto A; Yamamoto SR; Akimoto S; Kashiwagi H; Yanaga K
Hepatogastroenterology; 2010; 57(98):379-82. PubMed ID: 20583448
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of gastric carcinoid tumors].
Sang X; Gao W; Tang W
Zhonghua Wai Ke Za Zhi; 1999 Mar; 37(3):151-3. PubMed ID: 11829806
[TBL] [Abstract][Full Text] [Related]
20. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anaemia--regression of tumors by antrectomy. A case report.
Richards AT; Hinder RA; Harrison AC
S Afr Med J; 1987 Jul; 72(1):51-3. PubMed ID: 3603295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
